G
Gilles Edan
Researcher at French Institute of Health and Medical Research
Publications - 206
Citations - 23466
Gilles Edan is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Multiple sclerosis & Expanded Disability Status Scale. The author has an hindex of 49, co-authored 187 publications receiving 21785 citations. Previous affiliations of Gilles Edan include University of Rennes.
Papers
More filters
Journal ArticleDOI
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
W. Ian McDonald,A Compston,Gilles Edan,Donald E. Goodkin,Hans-Peter Hartung,Fred D. Lublin,Henry F. McFarland,Donald W. Paty,Chris H. Polman,Stephen C. Reingold,Magnhild Sandberg-Wollheim,William A. Sibley,Alan J. Thompson,Stanley van den Noort,Brian Y. Weinshenker,Jerry S. Wolinsky +15 more
TL;DR: The revised criteria facilitate the diagnosis of MS in patients with a variety of presentations, including “monosymptomatic” disease suggestive of MS, disease with a typical relapsing‐remitting course, and disease with insidious progression, without clear attacks and remissions.
Journal ArticleDOI
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".
Chris H. Polman,Stephen C. Reingold,Gilles Edan,Massimo Filippi,Hans-Peter Hartung,Ludwig Kappos,Fred D. Lublin,Luanne M. Metz,Henry F. McFarland,Paul O'Connor,Magnhild Sandberg-Wollheim,Alan J. Thompson,Brian G. Weinshenker,Jerry S. Wolinsky +13 more
TL;DR: New evidence and consensus now strengthen the role of these criteria in the multiple sclerosis diagnostic workup to demonstrate dissemination of lesions in time, to clarify the use of spinal cord lesions, and to simplify diagnosis of primary progressive disease.
Journal ArticleDOI
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.
Giancarlo Comi,Massimo Filippi,Frederik Barkhof,Luca Durelli,Gilles Edan,Oscar Fernandez,Hans-Peter Hartung,Pierrette A. Seeldrayers,Per Soelberg Sørensen,Marco Rovaris,Vittorio Martinelli,Otto R. Hommes +11 more
TL;DR: Interferon beta-1a treatment at an early stage of multiple sclerosis had significant positive effects on clinical and MRI outcomes.
Journal ArticleDOI
Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity
Richard Roxburgh,S. R. Seaman,T Masterman,Anke Hensiek,Stephen Sawcer,Sandra Vukusic,Iuliana Achiti,Christian Confavreux,M. Coustans,E. Le Page,Gilles Edan,G V McDonnell,Stanley Hawkins,Maria Trojano,Maria Liguori,Eleonora Cocco,Maria Giovanna Marrosu,Fabiana Tesser,Maurizio Leone,Alexandra Weber,Frauke Zipp,Bianca Miterski,Jörg T. Epplen,Annette Bang Oturai,P. Soelberg Sørensen,Elisabeth Gulowsen Celius,N. Téllez Lara,Xavier Montalban,Pablo Villoslada,Ana Martins da Silva,Monica Marta,Isabel Leite,Bénédicte Dubois,Justin P. Rubio,Helmut Butzkueven,Trevor J. Kilpatrick,Marcin P. Mycko,Krzysztof Selmaj,Maria Edite Rio,Maria José Sá,Giuseppe Salemi,Giovanni Savettieri,Jan Hillert,D. A. S. Compston +43 more
TL;DR: The Multiple Sclerosis Severity Score (MSSS) as mentioned in this paper measures the severity of a patient with multiple sclerosis using the Expanded Disability Status Scale (EDSS) score.
Journal ArticleDOI
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
Ludwig Kappos,Chris H. Polman,Mark S. Freedman,Gilles Edan,H.-P. Hartung,David Miller,Xavier Montalban,Frederik Barkhof,Lars Bauer,P. Jakobs,Christoph Pohl,Rupert Sandbrink +11 more
TL;DR: Interferon beta-1b 250 mug subcutaneously every other day delayed conversion to clinically definite multiple sclerosis, and should be considered as a therapeutic option in patients presenting with a first clinical event suggestive of multiple sclerosis.